## Form 51-102F3 **Material Change Report**

Item 1	Name and Address of Company
	AI/ML INNOVATIONS INC. (the " <b>Company</b> ") #203, 645 Fort St., Victoria, British Columbia, V8W 1G2
Item 2	Date of Material Change
	March 14, 2025
Item 3	News Release
	A news release announcing the material change was disseminated on March 14, 2025 through the facilities of Accesswire and was subsequently filed on SEDAR+ at www.sedarplus.ca.
Item 4	Summary of Material Change
	On March 14, 2025 the Company announced Paul Duffy, AIML's Chief Executive Officer, and Peter Kendall, AIML's President and Chief Commercialization Officer, have both been appointed to the Board. Mr. Duffy has also assumed the role of Executive Chairman, Simultaneously, Mark Orsmond, outgoing Executive Chair of the Board, and Michael Nemirow have stepped down from the Board and continue their involvement as strategic advisors.
Item 5	Full Description of Material Change
5.1	Full Description of Material Change
	Please refer to the Company's news release dated March 14, 2025, which is attached as Schedule "A" to this Material Change Report.
5.2	Disclosure for Restructuring Transactions
	Not Applicable.
Item 6	Reliance on subsection 7.1(2) of National Instrument 51-102
	Not Applicable.
Item 7	Omitted Information
	Not Applicable.
Item 8	Executive Officer
	Contact:Paul Duffy, Chief Executive OfficerTelephone:(778) 405-0882Email:info@aiml-innovations.com
Item 9	Date of Report
	March 14, 2025

Schedule "A" News Release



**NEWS RELEASE** 

# **AI/ML INNOVATIONS INC.**

# AIML Aligns Leadership for Growth and Shareholder Value Creation

- Paul Duffy Appointed Executive Chairman of the Board
- Peter Kendall Joins Board
- Seasoned Advisors Mark Orsmond and Michael Nemirow to Support AIML's Corporate Development Initiatives

**Vancouver, Canada** – March 14, 2025 – **AI/ML Innovations Inc.** ("**AIML**" or the "**Company**") (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) is pleased to announce key updates to its Board of Directors ("**Board**") as the Company enters an exciting new phase of growth and commercialization.

Paul Duffy, AIML's Chief Executive Officer, and Peter Kendall, AIML's President and Chief Commercialization Officer, have both been appointed to the Board. Mr. Duffy has also assumed the role of Executive Chairman, Simultaneously, Mark Orsmond, outgoing Executive Chair of the Board, and Michael Nemirow have stepped down from the Board and continue their involvement as strategic advisors.

These changes reflect AIML's strategic commitment to aligning with the Company's forward-looking focus on commercial execution, market penetration, and strategic partnerships. As AIML continues to advance its innovative portfolio of AI-driven healthcare technologies, this Board realignment ensures the Company is structured to accelerate growth, provide direct industry experience, and drive shareholder value.

### Paul Duffy, CEO and newly appointed Chairman of the Board, commented:

"We are entering an exciting new chapter at AIML, one defined by focus, execution, and scalable impact. Strengthening our Board with more industry participants to enhance a commercialization lens is a key part of our strategic evolution, and I'm honored to now serve in a governance capacity alongside Peter Kendall. I would like to express my deep gratitude to both Mark and Michael for their dedication, insights, and leadership during a foundational period for the Company. In particular, we are very grateful to Mark for the top-tier medical and professional team that is now part of our Company, and I look forward to continuing to work closely with him in his new advisory role." As part of this transition, Mark Orsmond and Michael Nemirow will continue to play a pivotal role in the Company's growth trajectory, supporting corporate development initiatives, strategic partnerships, and commercialization strategies.

AIML remains steadfast in its mission to deliver breakthrough solutions at the intersection of artificial intelligence and human health. These leadership transitions mark a meaningful step forward in realizing that vision.

#### For more information about AIML:

For detailed information please see AIML's website or the Company's filed documents at www.sedarplus.ca.

Contact: Blake Fallis (778) 405-0882 info@aiml-innovations.com

#### About AI/ML Innovations Inc. https://aiml-innovations.com/

AIML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence: (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through its wholly-owned subsidiaries, Quantum Sciences Ltd. and NeuralCloud Solutions Inc, strategic partnerships with Health Gauge Inc. (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 11.11% currently owned by AIML), AI Rx Inc. (70% owned by AIML), and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AIML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

On behalf of the Board of Directors: Paul Duffy, Chairman

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

The Canadian Securities Exchange has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains "forward-looking statements" within the meaning of the securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. In addition, we cannot assure that any patent will be issued as a result of a pending patent application or, if issued, whether it will be issued in a form that will be advantageous to us. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time at sedarplus.ca. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. The Company is not responsible for the contents of third- party websites.